Mohali plant supply constraints persist
Supplies from Mohali plant are not normal; issues with product prioritization and quality clearances are causing delays.
SUNPHARMA / Q3-FY24 / risks
Keep the risk register visible.
Sunpharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
CEQUA facing increased competition in dry eye space
CEQUA's market share has declined due to generic Restasis and new entrants with different mechanisms of action.
Red Sea supply chain disruption risk
Management is monitoring the Red Sea situation; potential for shipment delays if situation does not normalize.
Taro merger may not receive minority approval
The $43/share offer requires approval from Taro's minority shareholders; failure could derail the merger.